Cart
sales@molnova.com
CCI 007
CAS No. 939228-52-1
CCI 007 ( —— )
Catalog No. M24990 CAS No. 939228-52-1
CCI 007 is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia with IC50 of 3.5 uM against MLL-r leukemia cell line PER-485
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 81 | In Stock |
|
| 5MG | 125 | In Stock |
|
| 10MG | 200 | In Stock |
|
| 25MG | 394 | In Stock |
|
| 50MG | 584 | In Stock |
|
| 100MG | 833 | In Stock |
|
| 500MG | 1683 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCCI 007
-
NoteResearch use only, not for human use.
-
Brief DescriptionCCI 007 is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia with IC50 of 3.5 uM against MLL-r leukemia cell line PER-485
-
DescriptionCCI 007 is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia with IC50 of 3.5 uM against MLL-r leukemia cell line PER-485
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetHistone Demethylase
-
RecptorMLL-r
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number939228-52-1
-
Formula Weight336.4
-
Molecular FormulaC15H16N2O5S
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESO=C(OCC)COC(C=CC(C=C1SC(N)=NC1=O)=C2)=C2OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Somers K , Chudakova D A , Middlemiss S , et al. CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements[J]. Oncotarget, 2016, 7(29):46067-46087.
molnova catalog
related products
-
SGC-iMLLT
SGC-iMLLT is a potent and selective MLLT1/3-histone interactions inhibitor(IC50 = 0.26 μM),and is a first-in-class chemical probe displaying cellular target engagement of MLLT1(Kd = 0.129?μM) and MLLT3(Kd = 0.077?μM).
-
KDM5A covalent inhib...
KDM5A covalent inhibitor N71 is an irreversible KDM5A inhibitor (IC50=0.22 uM) that covalently interacts with Cys481.
-
M?89
M-89 inhibits the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction and has potential to treat MLL leukemia.?M-89 is a highly potent and specific menin inhibitor, with a Kd of 1.4 nM for binding to menin.
